Acyclovir stops herpes viruses from replicating by disguising itself as a DNA building block. Once a virus mistakes acyclovir for the real thing and tries to use it, viral DNA construction grinds to a halt. What makes acyclovir particularly clever is that it’s almost entirely inactive until a virus-infected cell switches it on, which is why it can target the virus without doing much harm to healthy cells.
How Acyclovir Gets Activated
Acyclovir sits dormant in your body until it enters a cell that’s been infected by a herpes virus. Inside that cell, a viral enzyme called thymidine kinase performs the first critical step: it attaches a phosphate group to acyclovir, essentially flipping the “on” switch. This is something healthy, uninfected cells can’t do efficiently because they lack that particular viral enzyme.
After that first activation step, your own cellular enzymes add two more phosphate groups, converting the drug into its fully active form: acyclovir triphosphate. This three-step phosphorylation process is central to how the drug works, and it’s also why acyclovir concentrates its effects where the virus is actively replicating rather than throughout your entire body.
Shutting Down Viral DNA Replication
Once fully activated, acyclovir triphosphate does two things simultaneously. First, it competes with the natural DNA building block (a nucleotide called deoxyguanosine triphosphate) for access to the viral DNA assembly machinery. The viral DNA polymerase, the enzyme responsible for copying viral genetic material, grabs acyclovir triphosphate and tries to incorporate it into a growing DNA strand just as it would a normal nucleotide.
Here’s the problem for the virus: acyclovir is missing a key piece of molecular structure that normal nucleotides have. When it gets inserted into the DNA chain, nothing else can attach after it. The chain simply stops growing. This is called chain termination. Worse still for the virus, its DNA polymerase binds tightly to the dead-end chain and gets stuck there, effectively inactivating the enzyme. So one molecule of acyclovir doesn’t just stop one chain. It also takes one copy of the virus’s replication machinery out of commission.
Why It Targets Viruses, Not Your Cells
Acyclovir’s selectivity comes from two layers of protection. The first is that initial activation step requiring viral thymidine kinase. Because uninfected cells don’t have this enzyme, very little acyclovir gets converted to its active form in healthy tissue.
The second layer is that the viral DNA polymerase is far more likely to grab and use acyclovir triphosphate than your own cellular DNA polymerases are. Your cells’ replication enzymes are better at recognizing acyclovir as a fake and rejecting it. That said, the selectivity isn’t infinite. Research measuring acyclovir’s preference for viral over human polymerases found the drug favors the viral enzyme by a factor of about 42, a meaningful margin but modest compared to some newer antivirals. This is part of why side effects can still occur, particularly at high doses or with prolonged use.
What Acyclovir Treats
Acyclovir is effective against several members of the herpesvirus family. Its primary uses include genital herpes (HSV-2), oral herpes or cold sores (HSV-1), chickenpox (varicella-zoster), and shingles (herpes zoster). It’s also used for more serious herpes infections like encephalitis, a rare but dangerous brain infection. The CDC lists acyclovir alongside valacyclovir and famciclovir as the three recommended antiviral options for genital herpes.
Treatment courses vary depending on the condition. A first episode of genital herpes typically calls for 7 to 10 days of oral acyclovir, while a recurrent outbreak might only need 5 days. Shingles requires higher doses taken five times daily for 7 days. The frequent dosing schedule is one of acyclovir’s practical drawbacks, which is partly why valacyclovir was developed as an alternative.
Absorption and How It Moves Through Your Body
Oral acyclovir has notably low bioavailability, meaning only about 15 to 30 percent of what you swallow actually reaches your bloodstream. Blood levels peak roughly 1.5 to 2.5 hours after taking a dose, and the drug has a plasma half-life of about three hours. Your kidneys handle most of the elimination, filtering the drug out relatively quickly, which is why multiple doses per day are necessary to keep levels high enough to suppress viral replication.
Valacyclovir was designed to solve the absorption problem. It’s a prodrug, meaning your body converts it into acyclovir after absorption. The key difference is that valacyclovir is absorbed much more completely, delivering roughly 3 to 5 times more acyclovir into your bloodstream compared to taking acyclovir directly by mouth. This allows for less frequent dosing (twice daily instead of three to five times daily for many conditions) while achieving higher drug levels.
Why It Doesn’t Cure Herpes
Acyclovir only works on viruses that are actively replicating. Herpesviruses have a latent phase where they hide quietly inside nerve cells without producing the viral enzymes acyclovir needs for activation. During latency, there’s no viral thymidine kinase being made, so acyclovir can’t get switched on and has nothing to target. This is why herpes infections recur: the virus retreats to nerve cells between outbreaks, completely invisible to the drug. Acyclovir shortens outbreaks and reduces their severity, but it can’t reach the dormant virus.
How Viruses Develop Resistance
Because acyclovir depends entirely on the viral thymidine kinase for its first activation step, viruses can develop resistance by mutating that enzyme. The most common resistance mechanism involves mutations in the thymidine kinase gene that change the shape of the enzyme’s binding site, preventing acyclovir from being recognized and phosphorylated. Without that first step, the drug stays inactive.
Specific mutations like Y172C disrupt the molecular interactions that hold acyclovir in the correct position for phosphorylation. Other mutations, like the Y53H/R163H combination, interfere with the enzyme’s ability to bind its energy source (ATP), which is also needed for the activation reaction. In both cases, the result is the same: the drug can’t be turned on. Resistance is rare in people with healthy immune systems but becomes a real concern in immunocompromised patients who take acyclovir for extended periods.
Kidney Effects and Hydration
The most significant potential side effect of acyclovir relates to your kidneys. Acyclovir is relatively insoluble in urine. As your kidneys filter and concentrate the drug, crystals can form inside the tiny tubes (tubules) of the kidney. These crystals obstruct the tubules, block normal urine flow, and can cause a rise in kidney function markers. The risk is highest with intravenous acyclovir, in people who are dehydrated, or in those who already have reduced kidney function.
Staying well hydrated is the most straightforward way to reduce this risk. Adequate fluid intake keeps urine dilute enough that acyclovir crystals are less likely to form. For intravenous administration in clinical settings, fluids are given before the drug to establish good hydration. If crystal-related kidney injury does occur, it’s generally reversible once the drug is stopped and fluid intake is increased to flush the crystals out.